Astria Therapeutics Analyst Ratings
Astria Therapeutics Analyst Ratings
Astria Therapeutics Analyst Ratings
Astria Therapeutics Analyst Ratings
Astria Therapeutics Analyst Ratings
Astria Therapeutics Analyst Ratings
Astria Therapeutics Analyst Ratings
Astria Therapeutics Analyst Ratings
Oppenheimer Adjusts Astria Therapeutics Price Target to $25 From $30, Maintains Outperform Rating
Wedbush Trims Astria Therapeutics' Price Target to $17 From $18, Keeps Outperform Rating
Wedbush Maintains Outperform on Astria Therapeutics, Lowers Price Target to $18
Astria Therapeutics Analyst Ratings
HC Wainwright & Co. Maintains Buy on Astria Therapeutics, Lowers Price Target to $18
Astria Therapeutics Analyst Ratings
Wedbush Trims Astria Therapeutics' Price Target to $25 From $26, Keeps Outperform Rating
Astria Therapeutics Analyst Ratings
Oppenheimer Reiterates Outperform on Astria Therapeutics, Maintains $30 Price Target
HC Wainwright & Co. Reiterates Buy on Astria Therapeutics, Maintains $20 Price Target
Evercore ISI Group Initiates Coverage On Astria Therapeutics With Outperform Rating, Announces Price Target of $18
Wedbush Adjusts Price Target on Astria Therapeutics to $26 From $27, Keeps Outperform Rating